| Chronic Obstructive Airway Disease
Breyna vs Nucala
Side-by-side clinical, coverage, and cost comparison for chronic obstructive airway disease.Deep comparison between: Breyna vs Nucala with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNucala has a higher rate of injection site reactions vs Breyna based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nucala but not Breyna, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Breyna
Nucala
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
SC injection
Every 4 weeks
IL-5 antagonist
Indications
- Asthma
- Chronic Obstructive Airway Disease
- Bronchitis, Chronic
- Pulmonary Emphysema
- Asthma
- Chronic rhinosinusitis with multiple nasal polyps
- Chronic Obstructive Airway Disease
- Eosinophilic granulomatosis with polyangiitis
- Hypereosinophilic syndrome
Dosing
Asthma (12 years and older) 2 inhalations of 80 mcg/4.5 mcg or 160 mcg/4.5 mcg twice daily by oral inhalation; starting dose based on asthma severity.
Asthma (6 to <12 years) 2 inhalations of 80 mcg/4.5 mcg twice daily by oral inhalation.
Chronic Obstructive Airway Disease, Bronchitis, Chronic, Pulmonary Emphysema 2 inhalations of 160 mcg/4.5 mcg twice daily by oral inhalation.
Asthma (>=12 years), Chronic rhinosinusitis with multiple nasal polyps, Chronic Obstructive Airway Disease 100 mg SC once every 4 weeks.
Asthma (6-11 years) 40 mg SC once every 4 weeks.
Eosinophilic granulomatosis with polyangiitis, Hypereosinophilic syndrome 300 mg SC once every 4 weeks, administered as 3 separate 100 mg injections at least 5 cm apart.
Contraindications
- Primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required
- Hypersensitivity to any ingredient in BREYNA
- History of hypersensitivity to mepolizumab or excipients in the formulation
Adverse Reactions
Most common (>=3%) Nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, oral candidiasis, bronchitis, influenza
Serious Serious asthma-related events (hospitalizations, intubations, death), cardiovascular and CNS effects, Candida albicans infection, pneumonia or lower respiratory tract infections in COPD, immunosuppression, hypercorticism, adrenal suppression
Postmarketing Angina pectoris, tachycardia, atrial fibrillation, cataract, glaucoma, oropharyngeal candidiasis, anaphylactic reaction, hyperglycemia, hypokalemia, tremor, dysphonia, hypotension, hypertension
Most common (>=3%) headache, injection site reaction, back pain, fatigue, oropharyngeal pain, arthralgia, diarrhea, urinary tract infection, cough, pruritus, eczema
Serious herpes zoster
Postmarketing hypersensitivity reactions including anaphylaxis
Pharmacology
Budesonide is an inhaled corticosteroid that suppresses inflammation by inhibiting multiple cell types and mediators involved in allergic and non-allergic inflammation; formoterol is a long-acting selective beta2-adrenergic agonist that relaxes bronchial smooth muscle by stimulating adenyl cyclase and increasing intracellular cyclic AMP.
Mepolizumab is an IL-5 antagonist (IgG1 kappa) that binds IL-5 with high affinity, blocking its binding to the alpha chain of the IL-5 receptor complex on eosinophils, thereby inhibiting IL-5 signaling and reducing eosinophil production and survival.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Breyna
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
Nucala
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (11/12) · Qty limit (11/12)
UnitedHealthcare
Breyna
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Nucala
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Breyna
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (1/3)
Nucala
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Breyna.
Cost estimate not availableAccessia Health: Asthma - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
BreynaView full Breyna profile
NucalaView full Nucala profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.